Amphion Innovations plc

Share Issuance

London and New York, 5 December 2017 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, today announces that the Company has issued 1,664,659 ordinary shares, representing 0.80% of the enlarged issued share capital, to a holder (“Note Holder”) of the Convertible Promissory Notes December 2008 - December 2017 (the “CPN”).  The Note Holder is converting its CPN Holding of £133,172.76 into Amphion ordinary shares at 8 pence per share.

An application has been made for the new ordinary shares to be admitted to trading on AIM. Admission of the 1,664,659 new ordinary shares, ranking pari passu with the existing ordinary shares, is expected on 8 December 2017. Following this allotment, the total issued share capital of the Company will be 209,175,888 ordinary shares with each ordinary share holding one voting right. This figure may be used by shareholders in the Company as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules. 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

For further information please contact

Amphion Innovations
Charlie Morgan
+1 212 210 6224

Panmure Gordon Limited (Nominated Adviser and Corporate Broker)
Freddy Crossley / Ryan McCarthy (Corporate Finance)
Charlie Leigh-Pemberton (Corporate Broking)
+44 (0)20 7886 2500

Northland Capital Partners Limited (Joint Corporate Broker)
Patrick Claridge / David Hignell (Corporate Finance)
John Howes / Mark Treharne (Corporate Broking)
+44 (0)20 3861 6600

Walbrook PR
Mike Wort / Paul McManus
+44 (0)20 7933 8780

About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses.

We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in a small number of Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies.